180 related articles for article (PubMed ID: 31905966)
21. PD-L1 expression in tumor lesions and soluble PD-L1 serum levels in patients with breast cancer: TNBC versus TPBC.
Yazdanpanah P; Alavianmehr A; Ghaderi A; Monabati A; Montazer M; Tahmasbi K; Farjadian S
Breast Dis; 2021; 40(1):43-50. PubMed ID: 33523034
[TBL] [Abstract][Full Text] [Related]
22. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773
[TBL] [Abstract][Full Text] [Related]
23. GBP5 Repression Suppresses the Metastatic Potential and PD-L1 Expression in Triple-Negative Breast Cancer.
Cheng SW; Chen PC; Lin MH; Ger TR; Chiu HW; Lin YF
Biomedicines; 2021 Apr; 9(4):. PubMed ID: 33916322
[TBL] [Abstract][Full Text] [Related]
24. Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting.
García-Teijido P; Cabal ML; Fernández IP; Pérez YF
Clin Med Insights Oncol; 2016; 10(Suppl 1):31-9. PubMed ID: 27081325
[TBL] [Abstract][Full Text] [Related]
25. Triple negative breast cancer - prognostic role of immune-related factors: a systematic review.
Stovgaard ES; Nielsen D; Hogdall E; Balslev E
Acta Oncol; 2018 Jan; 57(1):74-82. PubMed ID: 29168430
[TBL] [Abstract][Full Text] [Related]
26. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.
Xue Y; Gao S; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X; Wu R
Expert Opin Drug Deliv; 2021 Feb; 18(2):187-203. PubMed ID: 32954856
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy in triple-negative breast cancer.
Katz H; Alsharedi M
Med Oncol; 2017 Dec; 35(1):13. PubMed ID: 29255938
[TBL] [Abstract][Full Text] [Related]
28. Effect of anthracycline and taxane on the expression of programmed cell death ligand-1 and galectin-9 in triple-negative breast cancer.
Yoon HK; Kim TH; Park S; Jung H; Quan X; Park SJ; Han J; Lee A
Pathol Res Pract; 2018 Oct; 214(10):1626-1631. PubMed ID: 30139555
[TBL] [Abstract][Full Text] [Related]
29. Focal Adhesion Kinase Provides a Collateral Vulnerability That Can Be Leveraged to Improve mTORC1 Inhibitor Efficacy.
Cuellar-Vite L; Weber-Bonk KL; Abdul-Karim FW; Booth CN; Keri RA
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884439
[TBL] [Abstract][Full Text] [Related]
30. JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer.
Chen M; Pockaj B; Andreozzi M; Barrett MT; Krishna S; Eaton S; Niu R; Anderson KS
Clin Breast Cancer; 2018 Oct; 18(5):e1205-e1215. PubMed ID: 29933930
[TBL] [Abstract][Full Text] [Related]
31. Tinagl1 Suppresses Triple-Negative Breast Cancer Progression and Metastasis by Simultaneously Inhibiting Integrin/FAK and EGFR Signaling.
Shen M; Jiang YZ; Wei Y; Ell B; Sheng X; Esposito M; Kang J; Hang X; Zheng H; Rowicki M; Zhang L; Shih WJ; Celià-Terrassa T; Liu Y; Cristea I; Shao ZM; Kang Y
Cancer Cell; 2019 Jan; 35(1):64-80.e7. PubMed ID: 30612941
[TBL] [Abstract][Full Text] [Related]
32. Rational combination of immunotherapy for triple negative breast cancer treatment.
Li CW; Lim SO; Hsu JL; Hung MC
Chin Clin Oncol; 2017 Oct; 6(5):54. PubMed ID: 29129094
[TBL] [Abstract][Full Text] [Related]
33. Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.
Nair A; Chung HC; Sun T; Tyagi S; Dobrolecki LE; Dominguez-Vidana R; Kurley SJ; Orellana M; Renwick A; Henke DM; Katsonis P; Schmitt E; Chan DW; Li H; Mao S; Petrovic I; Creighton CJ; Gutierrez C; Dubrulle J; Stossi F; Tyner JW; Lichtarge O; Lin CY; Zhang B; Scott KL; Hilsenbeck SG; Sun J; Yu X; Osborne CK; Schiff R; Christensen JG; Shields DJ; Rimawi MF; Ellis MJ; Shaw CA; Lewis MT; Westbrook TF
Nat Med; 2018 May; 24(4):505-511. PubMed ID: 29578538
[TBL] [Abstract][Full Text] [Related]
34. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X
Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606
[TBL] [Abstract][Full Text] [Related]
35. FAK is Required for Tumor Metastasis-Related Fluid Microenvironment in Triple-Negative Breast Cancer.
Pan MR; Hou MF; Ou-Yang F; Wu CC; Chang SJ; Hung WC; Yip HK; Luo CW
J Clin Med; 2019 Jan; 8(1):. PubMed ID: 30609732
[TBL] [Abstract][Full Text] [Related]
36. Effects of two different immunotherapies on triple negative breast cancer in animal model.
Liu X; Hu J; Cao W; Qu H; Wang Y; Ma Z; Li F
Cell Immunol; 2013; 284(1-2):111-8. PubMed ID: 23973874
[TBL] [Abstract][Full Text] [Related]
37. Targeting NANOG and FAK via Cx26-derived Cell-penetrating Peptides in Triple-negative Breast Cancer.
Mulkearns-Hubert EE; Esakov Rhoades E; Ben-Salem S; Bharti R; Hajdari N; Johnson S; Myers A; Smith IN; Bandyopadhyay S; Eng C; Downs E; Lathia JD; Reizes O
Mol Cancer Ther; 2024 Jan; 23(1):56-67. PubMed ID: 37703580
[TBL] [Abstract][Full Text] [Related]
38. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
39. FOXM1 transcriptionally regulates expression of integrin β1 in triple-negative breast cancer.
Hamurcu Z; Kahraman N; Ashour A; Ozpolat B
Breast Cancer Res Treat; 2017 Jun; 163(3):485-493. PubMed ID: 28361350
[TBL] [Abstract][Full Text] [Related]
40. Efficiency of Cytokine-Induced Killer Cells in Combination with Chemotherapy for Triple-Negative Breast Cancer.
Li M; Wang Y; Wei F; An X; Zhang N; Cao S; Ren B; Zhang X; Ren X
J Breast Cancer; 2018 Jun; 21(2):150-157. PubMed ID: 29963110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
